Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
about
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenCombination anastrozole and fulvestrant in metastatic breast cancerDelaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerOptimal management of hormone receptor positive metastatic breast cancer in 2016Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast CancerCurrent medical treatment of estrogen receptor-positive breast cancerReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerReversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma.Potential role of aromatase inhibitors in the treatment of endometriosisAromatase inhibitors in post-menopausal endometriosis.Aromatase inhibitor strategies in metastatic breast cancer.The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer.Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients.During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.Aromatase inhibitors in stimulated IVF cycles.Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer.Ablative Therapies in Metastatic Breast Cancer: A Systematic Review.Tamoxifen induces hepatotoxicity and changes to hepatocyte morphology at the early stage of endocrinotherapy in mice.Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: Validation of the cut-off value of the Ki67 labeling index as a predictive factorInterpreting cancer biology: refining our therapeutic algorithm in breast cancer.Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer.Aromatase inhibitors in post-menopausal metastatic breast carcinoma.Progression of endocrine therapies for breast cancer: where are we headed?Is Age-targeted full-field digital mammography screening cost-effective in emerging countries? A micro simulation model.Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.Endocrine therapy of metastatic breast cancer.Identification of lncRNA FAM83H-AS1 as a novel prognostic marker in luminal subtype breast cancer.Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Breast cancer: beyond the cutting edge.Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor.Clomiphene citrate alternatives for the initial management of polycystic ovary syndrome: an evidence-based approach.mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.
P2860
Q24239985-A701DC52-045E-4ED8-91A7-AD6546205809Q24595386-3186A171-3483-499B-8E5F-08738F6821F7Q26770482-80AC6342-A513-4AAC-9352-9FBC269E3B0BQ26777683-501DD1B1-FE82-4E34-A64F-87EE78DA3D20Q26785496-9ED4FC44-FDAC-4E47-A61D-E8CD459062F7Q26795751-5528380B-68E3-499A-8553-84B0DF992F20Q28076777-DAFD6335-5E02-4855-BC7D-05A391DAA32DQ29620676-645D3B64-FAB5-49B5-8B82-8B51537F1513Q33943265-B59605D4-A131-479C-BE9D-2A0EAC644464Q33961506-07F68456-2E4F-4A71-AE95-1D4D4E94733EQ34194386-7DB3B69F-3706-4952-85FB-0CB976758259Q34272016-88E2FABB-7E5F-415D-B65F-B5D28F788985Q34534031-B5F814C6-57FC-4202-ACE8-9830129F760CQ34577709-BE50EF8C-8A88-4FFB-8CFA-9CA39DA9BB6BQ34979448-1C4D8551-F3BF-4015-BF53-F25B542FC1E3Q34993796-E7A62D01-CB9D-4E53-BEA2-6527BC847DB1Q35029586-8BA01766-1AFA-4ADC-90CC-754079531EB6Q35147441-AD3547A0-C7B3-40A8-876C-7F3C33212BE1Q35235623-9481F82A-E3E4-49DE-874D-4C27469686DDQ35752065-1679CC18-3735-4E77-B9DA-934636149BC3Q36304842-8BEF8C4E-139C-434B-873A-361D01FF16A2Q36344204-B24F9970-6DA2-4061-A1DB-235FC440630FQ36502027-A34C739D-F1E3-49C6-95A0-913280AB8BB3Q36530770-DCA0A73D-E188-4CE4-B00E-2AB5D8D985F7Q36740827-0A099963-BC96-43A9-BDF2-59B52D85CEB6Q36804566-AA6C7082-71F2-4160-9B25-FFB1556D3F80Q36823279-8063D987-3305-4E1D-B4CD-8A993C7BF946Q36861597-DCCBED22-E94F-4578-98D1-5EDDC2B4A380Q37004695-EEE39A94-9988-40B8-AB01-AEDEE093043BQ37076741-589A27A3-03FF-48D0-8AA4-A2007B432276Q37198196-6B9D7194-C2E2-4285-B298-7A2477B050A2Q37230676-D5E0C8AD-3E0E-4539-B919-BCE451F8EF2DQ37426959-C4FFFF61-6970-4DFA-8F58-B75FBB67FFA5Q37565213-E97485B0-FCB7-4798-B041-419B2051E518Q37598890-B45CF984-2510-4391-AC8B-7BF48B81ACC3Q37607281-3B91B3C7-0BB8-4CD9-8EE0-4A056386F26DQ37990857-78D5B4AA-694A-4A30-86F3-02A20A5C004AQ38007148-5531AAC8-14EB-4B8B-99B0-194B6588CA0CQ38352305-AADC1336-0742-4424-A3D4-69AD8FF2C5EEQ38374560-655A4DE6-DF81-4B6B-8330-784EB25FBF83
P2860
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Survival with aromatase inhibi ...... breast cancer: meta-analysis.
@ast
Survival with aromatase inhibi ...... breast cancer: meta-analysis.
@en
Survival with aromatase inhibi ...... breast cancer: meta-analysis.
@nl
type
label
Survival with aromatase inhibi ...... breast cancer: meta-analysis.
@ast
Survival with aromatase inhibi ...... breast cancer: meta-analysis.
@en
Survival with aromatase inhibi ...... breast cancer: meta-analysis.
@nl
prefLabel
Survival with aromatase inhibi ...... breast cancer: meta-analysis.
@ast
Survival with aromatase inhibi ...... breast cancer: meta-analysis.
@en
Survival with aromatase inhibi ...... breast cancer: meta-analysis.
@nl
P2093
P356
P1476
Survival with aromatase inhibi ...... breast cancer: meta-analysis.
@en
P2093
Davide Mauri
Nicholas Pavlidis
Nikolaos P Polyzos
P304
P356
10.1093/JNCI/DJJ357
P407
P577
2006-09-01T00:00:00Z